Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2022-10-21 Audit Report / Informat…
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Audit Report / Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, specifically reporting a change in the company's independent registered public accounting firm. It details the resignation of the former auditor and the engagement of a new auditor, including statements about disagreements and reportable events. The content focuses on auditor changes and related disclosures, which aligns with announcements about changes in accountants and financial statement matters. It is not a full audit report or annual report but a current report on a specific event related to accountants. Therefore, the document fits the category of Audit Report / Information (AR). The document length (5922 characters) and detailed content support this classification rather than a brief announcement or certification. Hence, the classification is AR with high confidence.
2022-10-21 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 12, 2022. It includes an update to shareholders in the form of a letter and a press release, both filed as exhibits. The content is brief (3116 characters) and primarily announces the issuance of these documents rather than containing substantive financial data or detailed reports. There is no indication of financial statements, audit results, management discussion, or other detailed report content. The document serves as a regulatory filing to inform about the shareholder letter and press release. According to the rules, such brief announcements with references to attached documents are classified as Regulatory Filings (RNS).
2022-09-13 English
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is under Item 5.02, which details the departure and appointment of certain officers, specifically the reappointment of the Controller as CFO and Principal Accounting Officer. There are no financial statements or detailed financial data present, and the document focuses on management changes. Therefore, this fits the category of Board/Management Information (MANG). The document length is 3766 characters, which is typical for an 8-K announcement rather than a full report. Hence, the classification is MANG with high confidence.
2022-09-09 English
PROSPECTUS SUPPLEMENT
Interim / Quarterly Report Classification · 100% confidence The document is a Prospectus Supplement filed pursuant to Rule 424(b)(4) related to a securities offering by ABVC BioPharma, Inc. It references and includes as an annex the company's Quarterly Report on Form 10-Q for the three months ended June 30, 2022. The text contains detailed financial statements, management discussion and analysis, risk factors, and other information typical of a Form 10-Q filing. The presence of unaudited consolidated financial statements and the quarterly period end date confirm this is a quarterly report. The document is not merely an announcement or a certification but contains substantive financial data and analysis. Therefore, the correct classification is Interim / Quarterly Report (IR).
2022-08-25 English
PROSPECTUS SUPPLEMENT
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q Quarterly Report filed with the SEC for the quarterly period ended June 30, 2022. It contains detailed unaudited consolidated financial statements, management's discussion and analysis, risk factors, legal proceedings, and other substantive financial information. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. The presence of financial statements and detailed analysis confirms it is a comprehensive interim/quarterly report. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2022-08-25 English
CURRENT REPORT
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The key content is about a notice of delisting or failure to satisfy a continued listing rule from Nasdaq due to the stock price being below $1.00 for 30 consecutive business days. The document discusses the deficiency letter, the compliance period, and potential consequences if compliance is not regained. This matches the definition of a Delisting Announcement (DLST), as it is an official notice regarding the company's stock potentially being removed from an exchange. The document length is 4752 characters, which is sufficient to be the actual announcement, not just a report publication announcement. Therefore, the correct classification is DLST with high confidence.
2022-08-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.